Editas Medicine (EDIT) Cash from Operations (2015 - 2025)
Editas Medicine's (EDIT) quarterly Cash from Operations came in at 30843000.0 in Q3 2025, up 41.35% year-on-year from 21820344.72 in Q3 2024, and up 38.57% on a QoQ basis from 50212000.0 in Q2 2025.
Editas Medicine (EDIT) Cash from Operations (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Cash from Operations data on file, last reported at 30843000.0 in Q3 2025.
- On a quarterly basis, Cash from Operations rose 41.35% year-over-year to 30843000.0 in Q3 2025; TTM through Sep 2025 was 179616000.0, a 1.18% increase from a year earlier, with the FY2024 full-year figure at 210284000.0, down 59.09% from the prior year.
- Cash from Operations for Q3 2025 stood at 30843000.0, up from 50212000.0 in the prior quarter.
- Over the last five years, Cash from Operations for EDIT reached as high as 22240000.0 in Q4 2023 and fell as low as 57062000.0 in Q2 2024.
- Historically, Cash from Operations has averaged 42761473.68 across 5 years, with a median of 42273000.0 in 2022.
- Across the five-year window, Cash from Operations surged 47.39% in 2023 and tumbled 128.25% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 34582000.0 in 2021, then decreased by 22.24% to 42273000.0 in 2022, then jumped by 47.39% to 22240000.0 in 2023, then tumbled by 128.25% to 50762000.0 in 2024, then soared by 39.24% to 30843000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Operations figures were 30843000.0 in Q3 2025, 50212000.0 in Q2 2025, and 47799000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -30.84 Mn |
| Sep 30, 2025 | -30.84 Mn |
| Jun 30, 2025 | -50.21 Mn |
| Jun 30, 2025 | -50.21 Mn |
| Mar 31, 2025 | -47.80 Mn |
| Mar 31, 2025 | -47.80 Mn |
| Dec 31, 2024 | -50.76 Mn |
| Dec 31, 2024 | -50.76 Mn |
| Sep 30, 2024 | -52.59 Mn |
| Sep 30, 2024 | -52.59 Mn |
| Jun 30, 2024 | -57.06 Mn |
| Jun 30, 2024 | -57.06 Mn |
| Mar 31, 2024 | -49.87 Mn |
| Mar 31, 2024 | -49.87 Mn |
| Dec 31, 2023 | -22.24 Mn |
| Dec 31, 2023 | -22.24 Mn |
| Sep 30, 2023 | -35.46 Mn |
| Sep 30, 2023 | -35.46 Mn |
| Jun 30, 2023 | -38.71 Mn |
| Jun 30, 2023 | -38.71 Mn |